Company Overview and News


Add IMMU
to your dashboard

Headline News

Best ETFs for 2018: The SPDR S&P Biotech ETF (XBI) Will Continue to Rock

2018-01-17 investorplace
This article is a part of InvestorPlace’s Best ETFs for 2018 contest. Johnson Research Group’s pick for the contest is the SPDR S&P Biotech (ETF) (NYSEARCA:XBI). (93-0)

BRIEF-Immunomedics Announces Agreement With University Of Wisconsin Carbone Cancer Center To Expand Sacituzumab Govitecan Into Prostate Cancer

2018-01-11 reuters
* IMMUNOMEDICS ANNOUNCES AGREEMENT WITH UNIVERSITY OF WISCONSIN CARBONE CANCER CENTER TO EXPAND SACITUZUMAB GOVITECAN (IMMU-132) INTO PROSTATE CANCER (26-0)

When The Bulls Growl And The Bears Moo - Stock Market Outlook 2018

2018-01-10 seekingalpha
Stocks remain in a major uptrend. Staying the course worked great in 2017 and remains an effective strategy even now. (701-4)

Your Daily Pharma Scoop: Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides Update, Axsome Suffers Setback

2018-01-10 seekingalpha
Today we will discuss the much-anticipated FDA briefing documents for Aradaigm’s (ARDM) Linhaliq. The documents were made available today ahead of the Ad Com meeting on Thursday, January 11th. (332-4)

EcoR1 Capital, LLC - All Holdings - 13F 13D 13G Filings - Fintel.io

2018-01-03 fintel.io
EcoR1 Capital, LLC has disclosed 39 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 758,201,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). EcoR1 Capital, LLC's top holdings are Assembly Biosciences, Inc. (NASDAQ:ASMB) , FibroGen, Inc. (NASDAQ:FGEN) , Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) , Ascendis Pharma AS (NASDAQ:ASND) , and Kura Oncology, Inc. (154-2)

Biotech Forum Daily Digest: Our Take On MiMedx

2017-12-05 seekingalpha
After a decent previous week, biotech slid on Monday as money rotated into energy and financial names. (106-3)

ImmunoMedics Should Be On Your Radar Before Phase 2 Breast Cancer Data Update

2017-12-04 seekingalpha
Updated phase 2 Metastatic Triple-Negative Breast cancer data should act as a major catalyst for the stock. (26-6)

Immunomedics, Full Study Data to be Presented December 6, 2017, BLA Application as Early as 1Q18

2017-11-28 accesswire
NEW YORK, NY / ACCESSWIRE / November 28, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Immunomedics, Inc. (NASDAQ: IMMU), a clinical-stage pharmaceutical company. The company's principal area of investigation is monoclonal antibody-based products capable of treating cancer, autoimmune disorders, and other diseases. (26-0)

Featured Company News - Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of Migraine

2017-11-20 accesswire
LONDON, UK / ACCESSWIRE / November 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN) ("Biohaven"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=BHVN. The Company announced on November 16, 2017, the completion of the enrollment in the first of its two registrational Phase-3 clinical trials, Study BHV3000-301, to establish the safety and efficacy of orally-dosed rimegepant for the acute treatment of migraine. (41-1)

Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock

2017-11-16 zacks
Investors in Immunomedics, Inc. (IMMU - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 17, 2017 $7.00 Put had some of the highest implied volatility of all equity options today. (39-2)

IMMU / Immunomedics, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-15 fintel.io
Immunomedics, Inc. (NASDAQ:IMMU) has 166 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 130,271,376 shares. Largest shareholders include venBio Select Advisor LLC, Seattle Genetics Inc /wa, Orbimed Advisors Llc, BlackRock Inc., and Acuta Capital Partners, Llc. (62-0)

Immunomedics (IMMU) Jumps: Stock Rises 5.4%

2017-11-15 zacks
Immunomedics, Inc. (IMMU - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $1.15 to $1.31 in the past one month time frame. (29-0)

Immunomedics' (IMMU) Q1 2018 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Immunomedics Incorporated First Quarter Fiscal 2018 Results Conference Call. As a reminder, this call is being recorded. Today is Thursday, November 9, 2017. (58-0)

Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?

2017-10-23 zacks
Investors in Immunomedics, Inc. (IMMU - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 19, 2018 $4 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. (78-0)

Stock Research Report

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The company's advanced proprietary technologies allow it to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of six clinical-stage product candidates.

The company believe that each of its antibodies has therapeutic potential either when administered as a naked antibody or when conjugated with chemotherapeutics, therapeutic radioisotopes (radiolabeled), cytokines or other toxins to create unique and potentially more effective treatment options. The attachment of various compounds to antibodies is intended to allow the delivery of these therapeutic agents to tumor sites with better specificity than conventional chemothe...

Click for full article
CUSIP: 452907108